BICO Group Past Earnings Performance
Past criteria checks 0/6
BICO Group's earnings have been declining at an average annual rate of -73.8%, while the Life Sciences industry saw earnings growing at 28.5% annually. Revenues have been growing at an average rate of 44.9% per year.
Key information
-73.8%
Earnings growth rate
-68.9%
EPS growth rate
| Life Sciences Industry Growth | 31.8% |
| Revenue growth rate | 44.9% |
| Return on equity | -50.5% |
| Net Margin | -61.8% |
| Next Earnings Update | 26 Nov 2024 |
Recent past performance updates
Recent updates
Here's Why BICO Group (STO:BICO) Can Afford Some Debt
Jul 01
The Market Doesn't Like What It Sees From BICO Group AB (publ)'s (STO:BICO) Earnings Yet As Shares Tumble 26%
Jun 08Why BICO Group AB (publ) (STO:BICO) Could Be Worth Watching
Dec 02Calculating The Fair Value Of BICO Group AB (publ) (STO:BICO)
May 20Is BICO Group AB (publ) (STO:BICO) Potentially Undervalued?
May 04Is BICO Group (STO:BICO) Using Too Much Debt?
Feb 09Health Check: How Prudently Does BICO Group (STO:BICO) Use Debt?
Oct 24Bullish: This Analyst Just Lifted Their Cellink AB (publ) (STO:CLNK B) Outlook For Next Year
Jul 22Revenue & Expenses Breakdown
How BICO Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,423 | -1,498 | 1,532 | 116 |
| 31 Mar 24 | 2,426 | -1,649 | 1,554 | 101 |
| 31 Dec 23 | 2,405 | -1,697 | 1,537 | 0 |
| 30 Sep 23 | 2,252 | -527 | 1,270 | 143 |
| 30 Jun 23 | 2,256 | -390 | 1,380 | 143 |
| 31 Mar 23 | 2,297 | -117 | 1,645 | 67 |
| 31 Dec 22 | 2,327 | -85 | 1,818 | 0 |
| 30 Sep 22 | 2,278 | 41 | 1,857 | 0 |
| 30 Jun 22 | 1,995 | -130 | 1,666 | 0 |
| 31 Mar 22 | 1,743 | -224 | 1,354 | 0 |
| 31 Dec 21 | 1,378 | -228 | 1,061 | 0 |
| 30 Sep 21 | 993 | -188 | 749 | 0 |
| 30 Jun 21 | 744 | -96 | 519 | 0 |
| 31 Mar 21 | 460 | -50 | 342 | 0 |
| 31 Dec 20 | 369 | -36 | 273 | 0 |
| 31 Aug 20 | 236 | -62 | 218 | 0 |
| 31 May 20 | 213 | -49 | 197 | 0 |
| 29 Feb 20 | 197 | -24 | 176 | 0 |
| 30 Nov 19 | 173 | -5 | 138 | 0 |
| 31 Aug 19 | 135 | 1 | 106 | 0 |
| 31 May 19 | 118 | 3 | 87 | 0 |
| 28 Feb 19 | 97 | 4 | 69 | 0 |
| 30 Nov 18 | 76 | 2 | 55 | 0 |
| 31 Aug 18 | 61 | 1 | 43 | 0 |
| 31 May 18 | 45 | 1 | 30 | 0 |
| 28 Feb 18 | 34 | -2 | 24 | 0 |
| 30 Nov 17 | 27 | -2 | 21 | 0 |
| 31 Aug 17 | 20 | -1 | 16 | 0 |
| 31 Aug 16 | 6 | -1 | 4 | 0 |
Quality Earnings: BICO is currently unprofitable.
Growing Profit Margin: BICO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BICO is unprofitable, and losses have increased over the past 5 years at a rate of 73.8% per year.
Accelerating Growth: Unable to compare BICO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BICO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (36%).
Return on Equity
High ROE: BICO has a negative Return on Equity (-50.48%), as it is currently unprofitable.